OmanDocSign in

Curriculum · Cardiovascular and Hypertension

Statin therapy: indication and monitoring

What it is

Statin therapy is high-, moderate- or low-intensity, and it is the intensity, not the drug name, that the guidelines ask for.

Causes and risk

Elevated cholesterol is a risk factor for IHD, and LDL cholesterol is the single most important subgroup that carries that risk. The other risk factors are smoking, hypertension, physical inactivity, obesity and diabetes mellitus, with age, sex and genetics as the major uncontrollable ones. So the decision to treat is a risk decision. In the nondiabetic with an abnormal lipid profile, start lifestyle modification (weight loss, increased physical activity, and medical nutrition therapy: Mediterranean style or Dietary Approaches to Stop Hypertension) and then look at the ASCVD risk: if 40 or older use the 10 year risk, if younger use the LIFETIME RISK. The bands are:

Primary prevention means no history of CV events, and that is where the risk assessment is needed. Secondary prevention means the patient already has a cardiovascular event and has been seen by a specialist, and there no risk assessment is done. Any patient with HTN needs a risk assessment, and any patient with DM should be on moderate intensity. The non-drug therapy has numbers of its own: decrease intake of fats to under 30% of total energy intake with saturated fats under 10%, decrease cholesterol intake to under 300 mg/d, replace saturated fats with monounsaturated or polyunsaturated fats, decrease alcohol intake to under 3-4 u/d in males and under 2-3 u/d in females, reduce weight, increase physical activity, and stop smoking.

How it is treated

Who gets a statin:

In the diabetic the target follows the risk: diabetic 40 years or older, moderate intensity, LDL under 2.6; diabetic with one CV risk factor, high intensity, LDL under 1.8; diabetic with more than one CV risk factor, high intensity, LDL under 1.4. In the nondiabetic the goal is to reach LDL under 2.6. Follow up 4-12 weeks after initiation or a change in dose, and then annually. In acute coronary syndrome the statin does not wait for a cholesterol result: start a high-intensity statin such as atorvastatin early, regardless of baseline cholesterol, LDL and HDL levels. In STEMI that is a high-dose statin, for example atorvastatin 80 mg, recommended for all patients with STEMI without a contraindication to statin therapy such as liver disease; all NSTEMI patients should receive a statin and a P2Y12 inhibitor. Statins are also given for the hyperlipidemia of nephrotic syndrome, and in fatty liver disease, where patients with elevated aminotransferase levels can be treated with statin therapy. Monitoring is set out on its own in the national guideline, and it is the part most often asked. Repeat the lipid profile 3 months after starting therapy and adjust the dose or add another drug if targets are not achieved. Liver function tests are done before initiating the therapy, then 3 months after starting treatment and at 12 months, and not again unless clinically indicated. Creatinine kinase runs on a different rule: there is no need to measure CK at baseline, it is measured only if the patient complains of muscle pain, and the statin is stopped if the CK level is more than 5 times the upper reference range. Before starting, assess the fasting total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides if fasting levels are not already available, the fasting blood glucose, liver function as transaminases, renal function, and TSH if dyslipidaemia is present. In diabetes, start treatment after optimizing lifestyle intervention and treatment of other modifiable risk factors and secondary causes of dyslipidaemia; in secondary prevention, with a history of CVD, start treatment immediately, irrespective of initial cholesterol levels. Statins are most effective taken in the evening. For primary prevention other than in diabetes, start a low-cost statin such as simvastatin 40 mg or atorvastatin 20 mg nocte. There is no target level for total or LDL cholesterol in primary prevention, and the lipid levels are not rechecked; review the drug therapy at least annually. For secondary prevention and diabetes, start a low-cost statin, and a higher intensity statin may be used in acute coronary syndrome; aim to decrease total cholesterol by 25% or to under 4 mmol/L and LDL cholesterol by 30% or to under 2.0 mmol/L, measuring the non-fasting total cholesterol 3 months after starting treatment or after any dose change, then 6-12 monthly once stable, and consider increasing the dose if target lipid levels are not met. If statins are not tolerated, consider a fibrate, an anion exchange resin, nicotinic acid, which is not for diabetes, or ezetimibe. In diabetes the national guideline sets it out by type and by age. Moderate-intensity statin therapy should be initiated or continued for adults 40 to 75 years of age with diabetes mellitus, and high-intensity therapy is reasonable for diabetic adults 40 to 75 years with diabetes-related complications, presence of ASCVD and presence of CVD risk factors, unless contraindicated. Little evidence exists for patients with type 2 diabetes who are younger than 40 years; for those under 40 with other ASCVD risk factors the patient and the health care provider discuss relative benefits and risks and consider moderate-intensity statin therapy. In type 1 diabetes, offer statin therapy for primary prevention of CVD to adults older than 40 years, or with diabetes for more than 10 years, or with established nephropathy, or with other CVD risk factors, starting with atorvastatin 20 mg. Without overt CVD the primary goal is a reduction in LDL cholesterol of about 30% from baseline and LDL cholesterol under 2.6 mmol/l. With overt CVD, or diabetes with end organ damage, it is a reduction of about 50% from baseline and LDL cholesterol under 1.8 mmol/l, using a higher dose statin. If targets are not reached on maximally-tolerated doses of statins, combination therapy using statins and other lipid-lowering agents such as ezetimibe may be considered, and if the target is still not achieved, consider referral to a lipid clinic.